home / stock / blrx / blrx news


BLRX News and Press, BioLineRx Ltd. From 07/01/21

Stock Information

Company Name: BioLineRx Ltd.
Stock Symbol: BLRX
Market: NASDAQ
Website: biolinerx.com

Menu

BLRX BLRX Quote BLRX Short BLRX News BLRX Articles BLRX Message Board
Get BLRX Alerts

News, Short Squeeze, Breakout and More Instantly...

BLRX - Microcaps mostly among premarkets gainers

Alterity Therapeutics Limited (ATHE) +57% on a new patent by USPTO.Birks Group (BGI) +49% on re-opening of its retail stores across Canada.Wunong Net Technology Company (WNW) +46%.Spero Therapeutics (SPRO) +23% on $40M equity investment from Pfizer.Bridgeline Digital (BLIN) +21...

BLRX - BioLineRx: A Top Candidate For A Takeover Before 2022 Ends

On May 4, the company crossed successfully a crucial hurdle, putting it en-route toward getting an FDA approval as early as next year. As is the case with all micro-cap biotechs, investors remain skeptical due to the expected cash burn until, surely after, a possible approval. Not...

BLRX - Stem Cells Role in the Anti-Aging Business

In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...

BLRX - BioLineRx Ltd.'s (BLRX) CEO Phil Serlin on Q1 2021 Results - Earnings Call Transcript

BioLineRx Ltd. (BLRX) Q1 2021 Earnings Conference Call May 26, 2021, 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Avi Vainstein - Chief Medical Officer Ella Sorani - Chief Development Officer Co...

BLRX - biolinerx EPS beats by $0.17

biolinerx (BLRX): Q1 GAAP EPS of -$0.02 beats by $0.17.The Company held $58.1M in cash, cash equivalents and short-term bank deposits as of March 31, 2021.Press Release For further details see: biolinerx EPS beats by $0.17

BLRX - BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update

BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update - Phase 3 GENESIS study in stem-cell mobilization (SCM) demonstrated highly statistically significant positive results across all primary and secondary endpoints - - ~90% of patients in trea...

BLRX - BioLineRx to Report First Quarter 2021 Results on May 26, 2021

BioLineRx to Report First Quarter 2021 Results on May 26, 2021 Management to hold a conference call at 10:00 a.m. EDT PR Newswire TEL AVIV, Israel , May 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmac...

BLRX - Why Stem Cell Stocks in 2021 Make Sense

Political change along with updated White House priorities have certainly created a need to review investment portfolios. As the national focus shifts from one area of fulfilling citizens' wants and needs to another, some industries are getting more attention while others are put on “hi...

BLRX - Parkinson's Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027

Palm Beach, FL – May 5, 2021 – Parkinson’s disease (PD) is a neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.  Symptoms generally develop sl...

BLRX - ATVI, TEVA, AYX and LYFT among notable premarket gainers

Chiasma (CHMA) +39% on Q1 results.Athenex (ATNX) +31% on Kuur Therapeutics acquisition.Ault Global Holdings (DPW) +30% on preliminary Q1 results.iBio (IBIO) +26% after resolving Fraunhofer USA lawsuitBig 5 Sporting Goods Corporation (BGFV) +22% on Q1 results.DAVIDsTEA...

Previous 10 Next 10